Guidelines for economic evaluations in Italy: Recommendations from the Italian group of pharmacoeconomic studies

Drug Information Journal

Volumn 35, Issue 1, 2001, Pages 189-201

  Capri, S ^a   Ceci, A ^a   Terranova, L ^a   Merlo, F ^a   Mantovani, L ^a   Attanasio, E ^a   Benzi, G ^a   Berto, P ^a   Bruzzi, P ^a   Bruzzone, M ^a   Colombo, G ^a   Fattore, G ^a   Massotti, M ^a   Negrini, C ^a   Palazzo, F ^a   Paoletti, R ^a   Pasotti, V ^a   Reggio, S ^a   Santi, L ^a   Serra, G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Italian Group for Pharmacoeconomic Studies; Italy; Pharmacoeconomics

Indexed keywords

COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC ASPECT; ECONOMIC EVALUATION; HEALTH CARE COST; ITALY; MATHEMATICAL MODEL; METHODOLOGY; PRIORITY JOURNAL; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW;

EID: 0035092541     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150103500122     Document Type: Review

References (44)

1. Inter-Ministerial Committee for Economic Planning. Identifying criteria for contracting on the price of innovative medicines. Decree of January 30, 1997
2. UK guidance on good practice in the conduct of economic evaluation of medicines
3. Economic analysis of health technologies and programs: A Spanish proposal for methodological standardization
4. Welfare propositions of economic and interpersonal comparisons of utility
5. The foundation of welfare economics
6. Methodological and conduct principles for pharmacoeconomic research
7. Economic evaluation techniques in healthcare. Reinventing the wheel?
8. Should clinical trials with concurrent economic analyses be blinded?
9. Modelling in economic evaluation: An avoidable fact of life
10. Economic analysis alongside clinical trials: Revisiting the methodological issues
11. The friction cost method for measuring indirect costs of disease
12. The friction cost method: A comment
13. How to calculate indirect costs in economic evaluation
14. Some reflections on cost-effectiveness analysis
15. Discounting of life-saving and other nonmonetary effects
16. Time preference for health in cost-effectiveness analysis
17. Rates of time preference and validation of the duration of life
18. Discounting and health benefits
19. Discounting in the economic evaluation of health care interventions
20. On what basis should health be discounted?
21. Time preference for health in cost-effectiveness analysis
22. On the discounting of gained life-years in cost-effectiveness analysis
23. Time in health: Can we measure individuals' "pure time preference"?
24. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care
25. Pulling cost-effectiveness analysis up by its boot-straps: A non-parametric approach to confidence interval estimation
26. Costs effects and C/E ratios alongside a clinical trial
27. Confidence intervals for cost-effectiveness ratios
28. Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem
29. Statistical inference for cost-effectiveness ratios
30. Sensitivity analysis in economic evaluation: A review of published studies
31. Guidelines for authors and peer reviewers of economic submissions to the BMJ Economic Evaluation Working Party
32. Evaluating the BMJ guidelines for economic submissions: Prospective audit of economic submissions to BMJ and the Lancet